Beyond Lantus: Sanofi Signs Diabetes Deal With Wellstat
This article was originally published in The Pink Sheet Daily
Executive Summary
For a total deal value of $350 million, Sanofi gains global rights to Wellstat's Phase II first-in-class oral insulin sensitizer.
You may also be interested in...
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: